Welcome to Multibagg AI
Log in to access personalized features
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q1 FY22
Investor Presentation
Q1 FY22
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Panacea Biotec Ltd (PANACEABIO) is currently trading at 547.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Panacea Biotec Limited is India's second largest vaccine producer and a research-based health management company, specializing in prescription products across various therapeutic areas. The company has a strong R&D background with collaborations with both national and international research organizations, and it holds product patents in multiple countries. Recent developments include the launch of innovative vaccines, such as the world's first fully liquid wP-IPV pentavalent vaccine, underscoring its leadership in vaccine innovation. Panacea Biotec has strategically divested certain assets, including pharmaceutical formulation brands to Mankind Pharma, while focusing on its core competencies in vaccines and biotechnology. Panacea Biotec's facilities have received international certifications and inspections, demonstrating compliance with global health and safety standards, enhancing its export potential.
Over the past 52 weeks, Panacea Biotec Ltd has traded between a low of ₹293.10 and a high of ₹647.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Panacea Biotec Ltd has a market capitalization of approximately 3,726.80. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Panacea Biotec Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -694.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,726.80 Cr, Panacea Biotec Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Panacea Biotec Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Panacea Biotec Ltd is -694.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock rose after Panacea Biotec said it completed enrolment for the Phase III trial of its dengue vaccine candidate DengiAll, enrolling 10,335 participants.
The Income Tax Appellate Tribunal (ITAT) cancelled a total tax demand of ₹3.29 billion (or ₹329 crore) for Panacea Biotec. The order deleted all expense disallowances for assessment years 2005-06 to 2012-13.
The Income Tax Appellate Tribunal (ITAT) issued an order on March 10, 2026, cancelling a tax demand of ₹329.49 crore against Panacea Biotec for the assessment years 2005-06 to 2012-13.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
132.90 | 3,901 Cr | 28.34 | 2.17 | 0.75 | 7.65 | 10.29 | 5.32 | ||
387.95 | 3,890 Cr | 60.59 | 5.85 | 0.03 | 9.66 | 11.45 | 4.78 | ||
608.45 | 3,727 Cr | -694.00 | 4.46 | 0.00 | -2.93 | -2.42 | -0.57 | ||
377.00 | 3,535 Cr | 34.66 | 4.50 | 0.11 | 12.98 | 12.14 | 6.46 | ||
2093.25 | 3,464 Cr | 30.07 | 5.72 | 1.15 | 19.03 | 24.66 | 14.52 | ||
374.00 | 3,443 Cr | 17.66 | 2.22 | 0.00 | 12.58 | 11.51 | 6.92 | ||
1311.30 | 3,288 Cr | 35.29 | 4.02 | 0.00 | 11.39 | 15.94 | 9.52 | ||
| Median: 7 Co. | — | 387.95 | 3,535 Cr | 30.07 | 4.46 | 0.03 | 11.39 | 11.51 | 6.46 |
Project launch
Panacea Biotec is a key partner in the newly launched DENSTAR project (start 1 Jun 2026, 48 months) to advance licensure of its tetravalent live‑attenuated dengue vaccine DengiAll in sSA via Phase 1/III and CHIM studies; EDCTP funding €11.09M.
Project launch
Panacea Biotec announced the DENSTAR project, a four‑year, EU‑funded consortium starting 1 June 2026 to advance licensure and facilitate global access of its tetravalent dengue vaccine DengiAll in sub‑Saharan Africa.
Panacea Biotec Limited is India's second largest vaccine producer and a research-based health management company, specializing in prescription products across various therapeutic areas.
The company has a strong R&D background with collaborations with both national and international research organizations, and it holds product patents in multiple countries.
Recent developments include the launch of innovative vaccines, such as the world's first fully liquid wP-IPV pentavalent vaccine, underscoring its leadership in vaccine innovation.
Panacea Biotec has strategically divested certain assets, including pharmaceutical formulation brands to Mankind Pharma, while focusing on its core competencies in vaccines and biotechnology.
Panacea Biotec's facilities have received international certifications and inspections, demonstrating compliance with global health and safety standards, enhancing its export potential.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,354 Cr
Moderate Risk
-624.7
34.1
—
4.5
647.50
293.10
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
3
Neutral
7
Bullish
4
Bearish
8
Neutral
7
Bullish
31
Bearish
5
Neutral
0
Bullish
27
